Articles related to SARCOMA
Immunotherapy for Sarcoma: A Work in Progress
Meaningful advances in sarcoma treatment have been painfully slow. Modern immunotherapy may change that. The article referenced by this editorial reports the results of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma. The relevance of this study furthers the data using novel immunotherapeutic strategies, which generate B- and T-cell responses for two rare sarcomas that can serve as a foundation for future trials.
Oncology, Medical March 22nd 2022
For the Primary Care Physician – Soft Tissue Sarcoma: Recognizing a Rare Disease
The finding of a soft tissue mass on the trunk or limbs can be the source of anxiety and distress for patients, and a diagnostic challenge for physicians. In most cases the masses are benign. But when the mass is soft tissue sarcoma, the benefit of skilled early detection by the astute primary care clinician is enormous.
Internal Medicine March 15th 2022
Synovial Sarcoma in Children, Adolescents, and Young Adults
This Original Report from the Journal of Clinical Oncology based on the ARST0332 trial concludes: “The risk-based treatment strategy used in ARST0332 produced favorable outcomes in patients with nonmetastatic synovial sarcoma (SS) relative to historical controls despite using RT less frequently and at lower doses. The outcome for metastatic SS remains unsatisfactory and new therapies are urgently needed.”
Internal Medicine December 21st 2021
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma
The conclusion from the study presented in the Journal of Clinical Oncology: “While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.”
Hematology/Oncology December 21st 2021
Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Reference Source: JAMA Network OpenDesign: Retrospective study of 8,953 patients from the National Cancer Database; compared the use of definitive treatment between 2004 and 2014 of 1,280 young adults (YAs, aged 18-39 years); 3,937 patients aged 40-64 years; and 3,756 patients age 65+.Results: Amputation – 8.1% (YAs), 5.5% (40-64), 5.3% (65+). Chemotherapy – 39.4% (YAs), 29.5% (40-64), 9.3% (65+). Radiation – 59.3% (YAs), 69.1% (40-64), 63.4% (65+). Unique to young adults, clinical stage II disease vs. stage I disease and positive surgical margins were not associated with the use of radiation.
Geriatrics September 7th 2021